Novo Nordisk B

New Wegovy tablet launch boosts Novo Nordisk’s obesity‑drug outlook: U.S. approval, higher patient adherence, and strong pricing strategy promise $800‑$1,000M first‑year sales and a 5‑7 year patent‑extended runway.

New FDA approval of oral Wegovy boosts Novo Nordisk shares, offering patients a convenient, effective weight‑loss option and driving the company’s growth in obesity therapy.

Discover how Novo Nordisk’s CagriSema and higher‑dose Wegovy reshape the obesity‑drug market, balancing clinical gains, pricing pressures, and competition.

Explore how Novo Nordisk’s purchase of Akero Therapeutics boosts its pipeline, beats patent pressures, and strengthens market position beyond diabetes.

Discover how Novo Nordisk’s pediatric push for Cagrisema and WHO backing aim to rebound share prices and dominate the growing obesity market.

New Zealand-based Novo Nordisk to launch Ozempic in India, targeting the growing diabetes and obesity market with a focus on efficacy, safety, and cost‑effective delivery.

Discover how Novo Nordisk’s potential addition of Cagrisema could reshape the $70B obesity market, boost its GLP‑1 portfolio, and influence investor sentiment.

Novo Nordisk plans a 7.2‑mg Wegovy dose, seeking fast FDA approval to meet high‑need patients and boost U.S. sales amid rising obesity‑drug competition.

New 7.2‑mg Wegovy dose could reshape obesity treatment, pricing, and payer plans—boosting Novo Nordisk’s US sales while offering stronger weight‑loss benefits and potential cost savings.

Novo Nordisk shares stay flat as CMS cuts prices for GLP‑1 drugs, while a modest ALS trial boost hints at future neuro‑protective potential.